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Objectives: Network meta-analyses (NMA) provide estimates of comparative 
efficacy for multiple treatments based on an analysis of connected networks of 
trial comparisons. A key concern is the comparability of treatment effect estimates 
from different trials. Where there is both indirect and direct evidence for one or 
more comparisons (‘loops’ in the network) it is possible to evaluate empirically the 
‘consistency’ of the network. MethOds: A variety of methods have been proposed 
to examine inconsistency including: (i) node-splitting where the direct and indirect 
estimates are compared across the network (ii) comparison to an ‘inconsistency’ 
model where estimates for each treatment comparison are allowed to be inde-
pendent, (iii) inclusion of treatment by design interaction terms, (iv) investigation 
of residual deviance estimates for individual trial arms, and (v) investigation of 
mixed predictive p-values. We compare the implementation and, most impor-
tantly, the interpretation of these methods using a previously published NMA in 
type 2 diabetes. In this analysis HbA1c was compared across six treatments in 
a network of 22 studies with multiple ‘loops’. Results: The methods agreed in 
showing the presence of inconsistency with the network. For example, the incon-
sistency model showed an improved fit (DIC -62.35) compared to the consistency 
model (DIC -60.25). The node splitting method identified statistically significant 
inconsistency in two treatment arcs (liraglutide 1.8mg vs placebo and liraglutide 
1.8mg vs exenatide QW). cOnclusiOns: The alternative methods vary in their 
ability to provide an omnibus ‘test’ of inconsistency across the network and their 
ability to identify which parts of the network contain inconsistencies. We highlight 
that none of the methods alone can identify individual studies as being the cause 
of inconsistencies and argue that we need to consider the whole structure of the 
network and the characteristics of the studies (in terms of treatments, subjects 
and design) within the network.
PDB17
The efficacy anD effecTiveness in hBa1c-Lowering is DePenDenT on 
BaseLine BoDy Mass inDex (BMi) for siTagLiPTin BuT noT canagLifLozin 
in The TreaTMenT of TyPe 2 DiaBeTes MeLLiTus (T2DM)
Diels J.1, Angermund R.2, Schroeder M.3, Worbes-Cerezo M.3, Thompson G.3
1Janssen Research & Development, Beerse, Belgium, 2Janssen-Cilag Germany, Mainz, Germany, 
3Janssen-Cilag UK, High Wycombe, UK
Objectives: To investigate HbA1c-reduction by baseline BMI in patients treated 
with canagliflozin or sitagliptin, using clinical trial and electronic medical record 
(EMR) data. MethOds: Patient-level data from two randomised controlled tri-
als (RCTs) were used to explore HbA1c-reduction from baseline after 52 weeks 
treatment with canagliflozin (100/300mg) or sitagliptin (100mg) by baseline 
BMI. Ordinary least squares (OLS) regression was performed with HbA1c, BMI, 
eGFR and demographics as covariates, in patients with metformin (MET) or 
metformin+glimepiride (MET+SU) background therapy. EMR-data (UK General 
Practitioner data from CPRD) on HbA1c over time in patients treated with sitag-
liptin were analysed by background therapy using repeated measures analysis, 
with baseline BMI, HbA1c and demographics as covariates. Results: In both RCTs 
sitagliptin showed a decreasing HbA1c-reduction by increasing baseline BMI, while 
efficacy of canagliflozin was independent of BMI. The estimated HbA1c-reduction 
(%) from baseline for sitagliptin in patients with baseline BMI of 25 vs. 40 varied 
between -0.87 to -0.58 (MET; Δ = 0.29, p= 0.01) and -0.87 to -0.54 (MET+SU; Δ = 0.33, 
p= 0.0014), while a non-significant increase in HbA1c-reduction was observed in 
high BMI-patients in all canagliflozin-arms (Δ between -0.04 and -0.07). EMR-
data showed similar decreasing effectiveness of sitagliptin in high BMI-patients. 
Estimated HbA1c-reduction (month 10; baseline HbA1c 9%) was significantly less 
(MET: Δ = 0.30, MET+SU: Δ = 0.35, p< 0.0001) in patients with BMI 40 vs. 25. No data 
for canagliflozin were yet available. Lower efficacy of sitagliptin in obese patients 
has been previously reported in the literature. cOnclusiOns: RCT and EMR-
data consistently show that the relative efficacy of anti-diabetic treatments may 
depend on baseline BMI. Reduced efficacy of sitagliptin and DPP-4 inhibitors in 
general in obese patients may be explained by a higher degree of insulin-resist-
ance. Efficacy of canagliflozin is independent of BMI, due to its insulin-independ-
ent mechanism of action. Patients’ BMI should be taken into account to select 
effective therapeutic options for patients with T2DM.
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Objectives: Comparative effectiveness of new oral anti-diabetic drugs in primary 
care practice remains poorly characterized. This presentation focus on the relevant 
statistical methods used to handle common potential bias related to real-world 
observational designs. MethOds: Multicenter, longitudinal, observational study, 
conducted in primary care in France. Participating physicians were to include 
adult type 2 diabetes patients initiating a treatment with metformin and sitag-
liptin dual therapy (M-Sit group) or metformin and sulfonylurea dual therapy 
(M-SU group). Planned follow-up period was three years. The primary endpoint 
was the treatment maintenance duration, from initiation of dual therapy to a 
strict change, defined as the addition, replacement or withdrawal of an agent used 
for initial dual therapy. Survival Kaplan-Meier analysis, multivariate Cox model 
adjusted on the propensity score in order to limit bias due to baseline imbalance 
between the two groups and sensitivity analyses including multiple imputations to 
deal with missing data have been performed. Results: A total of 3 453 patients 
have been analyzed: 1 874 in the M-Sit group and 733 in the M-SU group. 
In the principal analysis, the median treatment maintenance duration was 
20.2 months in the M-SU group and 43.2 months in the M-Sit group (p < 0.0001). 
guideline targets, among a cohort of individuals treated for T2DM in Riyadh, Saudi 
Arabia. MethOds: Charts from 455 adults with T2DM who visited the King Fahad 
National Guard Hospital from October 2009 to March 2010 (enrolment period) were 
systematically sampled until the target (n= 250) was reached. Haemoglobin A1c 
(HbA1c), LDL, and BP test results from enrolment to September 2011 were abstracted. 
The most recent test values were compared to guideline targets. The proportion 
of well-controlled (target met on all tests) and never-controlled (target not met on 
any test) subjects over the study period was calculated. Analyses were stratified 
by T2DM duration. Results: Forty-four percent of the cohort was male; at enrol-
ment, mean (SD) age was 61 (13) years and mean T2DM duration was 11 (8) years. 
At the most recent assessment, 36 subjects (14%) had HbA1c < 7%, 91 (36%) had 
HbA1c ≥ 9%, and 177 (72%) had LDL < 100mg/dL. Although 109 subjects (44%) met 
BP targets (< 130/80mmHg), 30% had BP ≥ 140/90mmHg. HbA1c, LDL and BP were 
well-controlled in 5.2%, 45.9%, and 8.4% of subjects, respectively, while 71.2%, 13.4% 
and 22.9% were never-controlled, respectively. The proportion of the cohort that 
was never-controlled for HbA1c increased with T2DM duration. cOnclusiOns: 
While rates of HbA1c control were low among subjects with T2DM, nearly half met 
BP targets and nearly three quarters met LDL targets. Given the increased risk of 
complications associated with poor control, achieving higher rates of control could 
reduce the burden of T2DM in Saudi Arabia.
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Objectives: To quantify the number and costs of relapses avoided over 2 
years in the first-line treatment of RRMS based on the findings of the Cochrane 
report. MethOds: An Excel-based financial model estimated the relapses and costs 
incurred by a hypothetical cohort of 1000 RRMS patients treated with first-line 
disease-modifying drugs (DMDs). The modelled cohort evaluated the consequences 
of treatment with subcutaneous (SC) interferon beta-1a versus intramuscular 
(IM) interferon beta-1a, as this was the only comparison whose data quality was 
assessed as ‘high’ by the Cochrane Review (Filippini et al., 2013). Risk of relapse 
was based on the 2-year data from the Cochrane Review network meta-analysis. 
The analysis was performed from a US payer perspective. The cost of a relapse was 
sourced from Panitch et al., 2005, and adjusted to 2012 US dollars. Net annual cost 
of therapy was based on wholesale acquisition cost. Given the model’s short time 
horizon, disability-related costs were not included as these tend to be an important 
economic driver only over the long-term progression of the disease. In order to test 
how variability in the model’s inputs might impact the analysis’ results, two-way 
sensitivity analyses were performed based on the reported 95% risk of relapse cred-
ible intervals for SC interferon beta-1a and IM interferon beta-1a. Results: In a 
hypothetical cohort of 1000 RRMS patients, treatment with SC interferon beta-1a 
is expected to result in the avoidance of 173 (sensitivity analysis range: -20 to 399) 
relapses versus IM interferon beta-1a over 2 years. Assuming a direct cost of relapse 
of $5141, this represents a savings of $890,212 (sensitivity analysis range: -$102,138 
to $2,052,934) versus IM interferon beta-1a. cOnclusiOns: Subcutaneous inter-
feron beta-1a is likely to result in fewer relapses and lower direct costs of relapse 
versus IM interferon beta-1a over a 2-year period treatment.
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Objectives: To conduct decision-focused mixed treatment comparisons (MTCs) 
of the relative efficacy and safety of a new DPP-4 inhibitor (DPP-4i), alogliptin 25mg 
daily compared to current DPP-4i’s used in UK clinical practice (sitagliptin, saxa-
gliptin, linagliptin, vildagliptin) in dual therapy for the treatment of type 2 diabetes 
mellitus (T2DM) in combination with metformin or sulfonylurea (SU). MethOds: A 
decision-focused systematic review was conducted to identify RCTs comparing the 
DPP-4i’s in combination with metformin or SU compared to metformin or SU alone 
or against each other in the target patient population. Separate Bayesian MTCs were 
conducted for each DPP-4i combination. Outcomes of interest were change in HbA1c 
from baseline (primary), weight change, proportion of patients HbA1c < 7%, and 
proportion of patients ≥ 1 hypoglycaemic episode. Fixed and random effects models 
were run with sensitivity analysis conducted to account for confounding factors 
(study length, baseline HbA1c), study heterogeneity and inconsistency. Results: 
Twenty-five RCTs met inclusion criteria for the MTCs. For the primary outcome, 
fixed effects models suffered from heterogeneity problems whilst random effect 
models struggled to estimate between trial heterogeneity. However, the base case 
and all sensitivity analyses showed the same results - alogliptin in combination with 
metformin or SU had a high probability of non-inferiority to comparator DPP-4’s in 
HbA1c change (61%-100% at a 0.3% HbA1cmargin). Deletion of trial outliers via lever-
age plots vastly improved model fit within fixed effects models whilst not changing 
underlying results. For all other outcomes alogliptin was shown to be comparable to 
alternative DPP-4i’s. cOnclusiOns: Alogliptin 25mg has comparable efficacy and 
safety as other DPP-4i’s at their recommended doses in UK clinical practice. This 
is in line with expectations based on prior meta-analyses of DPP-4i’s. The use of a 
decision-focused approach to the MTC enables a focus on the data of direct interest 
for clinical and HTA based decision making.
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